BUSULFEX Side Effects

7018103-4 | Malignant Neoplasm Progression, Skin Hyperpigmentation
on Sep 08, 2010 Female patient from JAPAN , 47 years of age, was diagnosed with stem cell transplant and was treated with Busulfex (View Usage). Patient experienced the following unwanted or unexpected effects: malignant neoplasm progression, skin hyperpigmentation. Busulfex dosage: . During the same period patient was treated with CYCLOPHOSPHAMIDE (View Cyclophosphamide Review and Cyclophosphamide Label ).

7005275-0 | Acute Graft Versus Host Disease In Intestine, Acute Graft Versus Host Disease In Skin, Bk Virus Infection, Clostridial Infection, Cystitis, Cytomegalovirus Infection, Gastrointestinal Haemorrhage, Pancreatic Disorder
Patient was taking Busulfex (View Usage). Patient had the following side effects: acute graft versus host disease in intestine, acute graft versus host disease in skin, bk virus infection, clostridial infection, cystitis, cytomegalovirus infection (What is cytomegalovirus infection?), gastrointestinal haemorrhage, pancreatic disorder on Sep 03, 2010 from GERMANY Additional patient health information: Female patient , child 6 years of age, was diagnosed with bone marrow conditioning regimen and. Busulfex dosage: 1.1 Mg/kg, Intravenous. During the same period patient was treated with CYCLOPHOSPHAMIDE (View Cyclophosphamide Review and Cyclophosphamide Label ), MELPHALAN HYDROCHLORIDE (View Melphalan Hydrochloride Review and Melphalan Hydrochloride Label ), CYCLOSPORINE (View Cyclosporine Review and Cyclosporine Label ).

7005130-6 | Acute Graft Versus Host Disease, Chronic Myeloid Leukaemia, Leukaemia Recurrent
Adverse event was reported on Sep 03, 2010 by a Female patient taking Busulfex (View Usage) (Dosage: 16 Mg/kg, Daily Dose) was diagnosed with bone marrow conditioning regimen and. Location: CHINA , 37 years of age, After Busulfex was administered, patient had the following side effects: acute graft versus host disease, chronic myeloid leukaemia, leukaemia recurrent. During the same period patient was treated with CYCLOPHOSPHAMIDE (View Cyclophosphamide Review and Cyclophosphamide Label ), CYCLOSPORINE (View Cyclosporine Review and Cyclosporine Label ), METHOTREXATE (View Methotrexate Review and Methotrexate Label ).

6980456-0 | Expressive Language Disorder, Graft Versus Host Disease, Hypertension, Hypertrophic Cardiomyopathy, Hypotonia, Leukodystrophy, Neuropathy Peripheral, Sepsis, Visual Impairment
on Aug 25, 2010 Female patient from CANADA , child 3 years of age, was treated with Busulfex (View Usage). Patient experienced the following unwanted or unexpected effects: expressive language disorder, graft versus host disease, hypertension, hypertrophic cardiomyopathy, hypotonia, leukodystrophy, neuropathy peripheral, sepsis (What is sepsis?), visual impairment. Busulfex dosage: . During the same period patient was treated with CYCLOPHOSPHAMIDE (View Cyclophosphamide Review and Cyclophosphamide Label ), ANTI THYMOCYTE GLOBULIN NOS (View Anti-thymocyte Globulin Nos Review and Anti-thymocyte Globulin Nos Label ), METHYLPREDNISOLONE (View Methylprednisolone Review and Methylprednisolone Label ), CYCLOSPORINE (View Cyclosporine Review and Cyclosporine Label ).


6979690-5 | Chronic Graft Versus Host Disease, Leukaemia Recurrent, Skin Nodule, Treatment Noncompliance
on Aug 24, 2010 Male patient from GREECE , 57 years of age, was diagnosed with stem cell transplant and was treated with Busulfex (View Usage). Patient had the following side effects: chronic graft versus host disease, leukaemia recurrent, skin nodule, treatment noncompliance. Busulfex dosage: 8 Mg/kg. During the same period patient was treated with FLUDARABINE PHOSPHATE (View Fludarabine Phosphate Review and Fludarabine Phosphate Label ), ATG (ANTILYMPHOC YTE IMMUNOGLOBULIN (HORSE)) (View Atg (antilymphoc Yte Immunoglobulin (horse)) Review and Atg (antilymphoc Yte Immunoglobulin (horse)) Label ), CYCLOPHOSPHAMIDE (View Cyclophosphamide Review and Cyclophosphamide Label ), MYCOPHENOLATE MOFETIL (View Mycophenolate Mofetil Review and Mycophenolate Mofetil Label ).

6978824-6 | Hypercalcaemia
Patient was taking Busulfex (View Usage). After Busulfex was administered, patient had the following side effects: hypercalcaemia on Aug 24, 2010 from UNITED STATES Additional patient health information: Female patient , 33 years of age, was diagnosed with stem cell transplant and. Busulfex dosage: 2 Mg/kg, Bid,. During the same period patient was treated with FLUDARABINE PHOSPHATE (View Fludarabine Phosphate Review and Fludarabine Phosphate Label ), ANTI THYMOCYTE GLOBULIN NOS (View Anti-thymocyte Globulin Nos Review and Anti-thymocyte Globulin Nos Label ).

6978820-9 | Graft Versus Host Disease, Liver Disorder, Transplant Failure
Adverse event was reported on Aug 24, 2010 by a Female patient taking Busulfex (View Usage) (Dosage: 2 Mg/kg, Bid,) was diagnosed with stem cell transplant and. Location: UNITED STATES , child 1 years of age, Patient experienced the following unwanted or unexpected effects: graft versus host disease, liver disorder, transplant failure. During the same period patient was treated with FLUDARABINE PHOSPHATE (View Fludarabine Phosphate Review and Fludarabine Phosphate Label ), ANTI THYMOCYTE GLOBULIN NOS (View Anti-thymocyte Globulin Nos Review and Anti-thymocyte Globulin Nos Label ).

6978368-1 | Graft Versus Host Disease, Haemorrhage Intracranial, Pulmonary Haemorrhage
on Aug 24, 2010 Female patient from UNITED STATES , child 2 years of age, was diagnosed with stem cell transplant and was treated with Busulfex (View Usage). Patient had the following side effects: graft versus host disease, haemorrhage intracranial, pulmonary haemorrhage. Busulfex dosage: 2 Mg/kg, Bid,. During the same period patient was treated with FLUDARABINE PHOSPHATE (View Fludarabine Phosphate Review and Fludarabine Phosphate Label ), ANTI THYMOCYTE GLOBULIN NOS (View Anti-thymocyte Globulin Nos Review and Anti-thymocyte Globulin Nos Label ).

6978340-1 | Hypercalcaemia
on Aug 24, 2010 Female patient from UNITED STATES , 24 years of age, was diagnosed with stem cell transplant and was treated with Busulfex (View Usage). After Busulfex was administered, patient had the following side effects: hypercalcaemia. Busulfex dosage: 2 Mg/kg, Bid,. During the same period patient was treated with FLUDARABINE PHOSPHATE (View Fludarabine Phosphate Review and Fludarabine Phosphate Label ), ANTI THYMOCYTE GLOBULIN NOS (View Anti-thymocyte Globulin Nos Review and Anti-thymocyte Globulin Nos Label ).

6978338-3 | Anaemia Haemolytic Autoimmune
Patient was taking Busulfex (View Usage). Patient experienced the following unwanted or unexpected effects: anaemia haemolytic autoimmune on Aug 24, 2010 from UNITED STATES Additional patient health information: Female patient , child 4 years of age, was diagnosed with stem cell transplant and. Busulfex dosage: 2 Mg/kg, Bid,. During the same period patient was treated with FLUDARABINE PHOSPHATE (View Fludarabine Phosphate Review and Fludarabine Phosphate Label ), ANTI THYMOCYTE GLOBULIN NOS (View Anti-thymocyte Globulin Nos Review and Anti-thymocyte Globulin Nos Label ), CYCLOSPORINE (View Cyclosporine Review and Cyclosporine Label ), MYCOPHENOLATE MOFETIL (View Mycophenolate Mofetil Review and Mycophenolate Mofetil Label ).

6978334-6 | Hypercalcaemia, Sepsis
Adverse event was reported on Aug 24, 2010 by a Female patient taking Busulfex (View Usage) (Dosage: 2 Mg/kg, Bid,) was diagnosed with stem cell transplant and. Location: UNITED STATES , 28 years of age, Patient had the following side effects: hypercalcaemia, sepsis (What is sepsis?). During the same period patient was treated with FLUDARABINE PHOSPHATE (View Fludarabine Phosphate Review and Fludarabine Phosphate Label ), ANTI THYMOCYTE GLOBULIN NOS (View Anti-thymocyte Globulin Nos Review and Anti-thymocyte Globulin Nos Label ).

6978081-0 | Condition Aggravated, Hypercalcaemia, Rash
on Aug 24, 2010 Female patient from UNITED STATES , 36 years of age, was diagnosed with stem cell transplant and was treated with Busulfex (View Usage). After Busulfex was administered, patient had the following side effects: condition aggravated, hypercalcaemia, rash (What is rash?). Busulfex dosage: 2 Mg/kg, Bid,. During the same period patient was treated with FLUDARABINE PHOSPHATE (View Fludarabine Phosphate Review and Fludarabine Phosphate Label ), ANTI THYMOCYTE GLOBULIN NOS (View Anti-thymocyte Globulin Nos Review and Anti-thymocyte Globulin Nos Label ).

6971805-8 | Malignant Neoplasm Progression, Non-hodgkin's Lymphoma Recurrent
on Aug 20, 2010 Female patient from POLAND , 50 years of age, was diagnosed with stem cell transplant and was treated with Busulfex (View Usage). Patient experienced the following unwanted or unexpected effects: malignant neoplasm progression, non-hodgkin's lymphoma recurrent. Busulfex dosage: 6.4 Mg/kg, Intravenous. During the same period patient was treated with CLADRIBINE (View Cladribine Review and Cladribine Label ), CAMPATH (View Campath Review and Campath Label ), CYCLOSPORINE (View Cyclosporine Review and Cyclosporine Label ), ACYCLOVIR (View Acyclovir Review and Acyclovir Label ), PENICILLIN (BENZYLPENICILLIN SODIUM) (View Penicillin (benzylpenicillin Sodium) Review and Penicillin (benzylpenicillin Sodium) Label ), SULFAMETHOXAZOLE AND TRIMETHOPRIM (View Sulfamethoxazole And Trimethoprim Review and Sulfamethoxazole And Trimethoprim Label ).

6971802-2 | Acute Myeloid Leukaemia Recurrent, Hepatitis C, Malignant Neoplasm Progression
Patient was taking Busulfex (View Usage). Patient had the following side effects: acute myeloid leukaemia recurrent, hepatitis c (What is hepatitis c?), malignant neoplasm progression on Aug 20, 2010 from POLAND Additional patient health information: Female patient , 50 years of age, was diagnosed with stem cell transplant and. Busulfex dosage: 6.4 Mg/kg, Intravenous. During the same period patient was treated with CLADRIBINE (View Cladribine Review and Cladribine Label ), CAMPATH (View Campath Review and Campath Label ), CYCLOSPORINE (View Cyclosporine Review and Cyclosporine Label ), ACYCLOVIR (View Acyclovir Review and Acyclovir Label ), PENICILLIN (BENZYLPENICILLIN SODIUM) (View Penicillin (benzylpenicillin Sodium) Review and Penicillin (benzylpenicillin Sodium) Label ), SULFAMETHOXAZOLE AND TRIMETHOPRIM (View Sulfamethoxazole And Trimethoprim Review and Sulfamethoxazole And Trimethoprim Label ).

6971788-0 | Chronic Lymphocytic Leukaemia, Leukaemia Recurrent, Malignant Neoplasm Progression
Adverse event was reported on Aug 20, 2010 by a Male patient taking Busulfex (View Usage) (Dosage: 6.4 Mg/kg, Intravenous) was diagnosed with stem cell transplant and. Location: POLAND , 51 years of age, After Busulfex was administered, patient had the following side effects: chronic lymphocytic leukaemia, leukaemia recurrent, malignant neoplasm progression. During the same period patient was treated with CLADRIBINE (View Cladribine Review and Cladribine Label ), CAMPATH (View Campath Review and Campath Label ), CYCLOSPORINE (View Cyclosporine Review and Cyclosporine Label ), ACYCLOVIR (View Acyclovir Review and Acyclovir Label ), PENICILLIN (BENZYLPENICILLIN SODIUM) (View Penicillin (benzylpenicillin Sodium) Review and Penicillin (benzylpenicillin Sodium) Label ), SULFAMETHOXAZOLE W TRIMETHOPRIM (SULFAMETHOXAZOLE W TRIMETHOPRIM) (View Sulfamethoxazole W Trimethoprim (sulfamethoxazole W Trimethoprim) Review and Sulfamethoxazole W Trimethoprim (sulfamethoxazole W Trimethoprim) Label ).

6971787-9 | Leukaemia Recurrent, Malignant Neoplasm Progression, T-cell Prolymphocytic Leukaemia
on Aug 20, 2010 Male patient from POLAND , 26 years of age, was diagnosed with stem cell transplant and was treated with Busulfex (View Usage). Patient experienced the following unwanted or unexpected effects: leukaemia recurrent, malignant neoplasm progression, t-cell prolymphocytic leukaemia. Busulfex dosage: 6.4 Mg/kg, Intravenous. During the same period patient was treated with CLADRIBINE (View Cladribine Review and Cladribine Label ), CAMPATH (View Campath Review and Campath Label ), CYCLOSPORINE (View Cyclosporine Review and Cyclosporine Label ), ACYCLOVIR (View Acyclovir Review and Acyclovir Label ), PENICILLIN (BENZYLPENICILLIN SODIUM) (View Penicillin (benzylpenicillin Sodium) Review and Penicillin (benzylpenicillin Sodium) Label ), SULFAMETHOXAZOLE AND TRIMETHOPRIM (View Sulfamethoxazole And Trimethoprim Review and Sulfamethoxazole And Trimethoprim Label ).

6971786-7 | Chimerism, Leukaemia Recurrent
on Aug 20, 2010 Male patient from POLAND , 45 years of age, was diagnosed with stem cell transplant and was treated with Busulfex (View Usage). Patient had the following side effects: chimerism, leukaemia recurrent. Busulfex dosage: 6.4 Mg/kg, Iintravenous. During the same period patient was treated with CLADRIBINE (View Cladribine Review and Cladribine Label ), CAMPATH (View Campath Review and Campath Label ), CYCLOSPORINE (View Cyclosporine Review and Cyclosporine Label ), ACYCLOVIR (View Acyclovir Review and Acyclovir Label ), PENICILLIN (BENZYLPENICILLIN SODIUM) (View Penicillin (benzylpenicillin Sodium) Review and Penicillin (benzylpenicillin Sodium) Label ), SULFAMETHOXAZOLE AND TRIMETHOPRIM (View Sulfamethoxazole And Trimethoprim Review and Sulfamethoxazole And Trimethoprim Label ).

6971785-5 | Acute Myeloid Leukaemia Recurrent, Malignant Neoplasm Progression
Patient was taking Busulfex (View Usage). After Busulfex was administered, patient had the following side effects: acute myeloid leukaemia recurrent, malignant neoplasm progression on Aug 20, 2010 from POLAND Additional patient health information: Male patient , 56 years of age, was diagnosed with stem cell transplant and. Busulfex dosage: 6.4 Mg/kg, Intravenous. During the same period patient was treated with CLADRIBINE (View Cladribine Review and Cladribine Label ), CAMPATH (View Campath Review and Campath Label ), CYCLOSPORINE (View Cyclosporine Review and Cyclosporine Label ), ACYCLOVIR (View Acyclovir Review and Acyclovir Label ), PENICILLIN (BENZYLPENICILLIN SODIUM) (View Penicillin (benzylpenicillin Sodium) Review and Penicillin (benzylpenicillin Sodium) Label ), SULFAMETHOXAZOLE AND TRIMETHOPRIM (View Sulfamethoxazole And Trimethoprim Review and Sulfamethoxazole And Trimethoprim Label ).

6930119-2 | Acute Myocardial Infarction
Adverse event was reported on Aug 03, 2010 by a Male patient taking Busulfex (View Usage) (Dosage: ) was diagnosed with essential thrombocythaemia and. Location: FRANCE , 40 years of age, Patient experienced the following unwanted or unexpected effects: acute myocardial infarction. During the same period patient was treated with ASPIRIN (View Aspirin Review and Aspirin Label ).

6930094-0 | Arterial Thrombosis, Deep Vein Thrombosis
on Aug 03, 2010 Female patient from FRANCE , 37 years of age, was diagnosed with essential thrombocythaemia and was treated with Busulfex (View Usage). Patient had the following side effects: arterial thrombosis, deep vein thrombosis (What is deep vein thrombosis?). Busulfex dosage: . During the same period patient was treated with ACETYLSALICYLIC ACID (ACETYLSALICYCLIC ACID) (View Acetylsalicylic Acid (acetylsalicyclic Acid) Review and Acetylsalicylic Acid (acetylsalicyclic Acid) Label ).

6913582-2 | Arterial Thrombosis Limb, Deep Vein Thrombosis
on Jul 19, 2010 Female patient from FRANCE , 37 years of age, was diagnosed with essential thrombocythaemia and was treated with Busulfex (View Usage). After Busulfex was administered, patient had the following side effects: arterial thrombosis limb, deep vein thrombosis (What is deep vein thrombosis?). Busulfex dosage: . During the same period patient was treated with ASPIRIN (View Aspirin Review and Aspirin Label ).

6913579-2 | Acute Myocardial Infarction
Patient was taking Busulfex (View Usage). Patient experienced the following unwanted or unexpected effects: acute myocardial infarction on Jul 19, 2010 from FRANCE Additional patient health information: Male patient , 40 years of age, was diagnosed with essential thrombocythaemia and. Busulfex dosage: . During the same period patient was treated with ASPIRIN (View Aspirin Review and Aspirin Label ).

6913577-9 | Deep Vein Thrombosis
Adverse event was reported on Jul 19, 2010 by a Male patient taking Busulfex (View Usage) (Dosage: ) was diagnosed with essential thrombocythaemia and. Location: FRANCE , 38 years of age, Patient had the following side effects: deep vein thrombosis (What is deep vein thrombosis?).

6909380-6 | Chronic Graft Versus Host Disease, Cytomegalovirus Viraemia, Deafness Neurosensory, Ovarian Failure
on Jul 20, 2010 Female patient from UNITED STATES , 16 years of age, was diagnosed with stem cell transplant and was treated with Busulfex (View Usage). After Busulfex was administered, patient had the following side effects: chronic graft versus host disease, cytomegalovirus viraemia, deafness neurosensory, ovarian failure. Busulfex dosage: 0.8 Mg/kg, Q6hr, Intravenous. During the same period patient was treated with ANTITHYMOCYTE IMMUNOGLOBULIN (ANTITHYMOCYTE IMMUGLOBULIN) (View Antithymocyte Immunoglobulin (antithymocyte Immuglobulin) Review and Antithymocyte Immunoglobulin (antithymocyte Immuglobulin) Label ), CYCLOPHOSPHAMIDE (View Cyclophosphamide Review and Cyclophosphamide Label ), CYCLOSPORINE (View Cyclosporine Review and Cyclosporine Label ), PREDNISONE (View Prednisone Review and Prednisone Label ), PHENYTOIN (View Phenytoin Review and Phenytoin Label ), FILGRASTIM (FILGRASTIM) (View Filgrastim (filgrastim) Review and Filgrastim (filgrastim) Label ).

6909369-7 | Acute Graft Versus Host Disease In Liver, Chronic Graft Versus Host Disease, Convulsion, Cytomegalovirus Viraemia, Pneumonia Pneumococcal, Reversible Posterior Leukoencephalopathy Syndrome, Septic Shock, Staphylococcal Infection
on Jul 20, 2010 Female patient from UNITED STATES , child 9 years of age, was diagnosed with stem cell transplant and was treated with Busulfex (View Usage). Patient experienced the following unwanted or unexpected effects: acute graft versus host disease in liver, chronic graft versus host disease, convulsion, cytomegalovirus viraemia, pneumonia pneumococcal, reversible posterior leukoencephalopathy syndrome, septic shock, staphylococcal infection (What is staphylococcal infection?). Busulfex dosage: 0.8 Mg/kg, Q6hr, Intravenous. During the same period patient was treated with ANTI THYMOCYTE GLOBULIN NOS (View Anti-thymocyte Globulin Nos Review and Anti-thymocyte Globulin Nos Label ), CYCLOPHOSPHAMIDE (View Cyclophosphamide Review and Cyclophosphamide Label ), CYCLOSPORINE (View Cyclosporine Review and Cyclosporine Label ), PREDNISONE (View Prednisone Review and Prednisone Label ), PHENYTOIN (View Phenytoin Review and Phenytoin Label ).

6909368-5 | Convulsion, Diabetes Insipidus, Failure To Thrive, Haemorrhage Intracranial, Multi-organ Failure, Sepsis
Patient was taking Busulfex (View Usage). Patient had the following side effects: convulsion, diabetes insipidus (What is diabetes insipidus?), failure to thrive, haemorrhage intracranial, multi-organ failure, sepsis (What is sepsis?) on Jul 20, 2010 from UNITED STATES Additional patient health information: Male patient , 14 years of age, was diagnosed with stem cell transplant and. Busulfex dosage: 0.8 Mg/kg Q6hr Intravenous. During the same period patient was treated with ANTITHYMOCYTE IMMUNOGLOBULIN (ANTITHYMOCTE IMMUNOGLOBULIN) (View Antithymocyte Immunoglobulin (antithymocte Immunoglobulin) Review and Antithymocyte Immunoglobulin (antithymocte Immunoglobulin) Label ), CYCLOPHOSPHAMIDE (View Cyclophosphamide Review and Cyclophosphamide Label ), CYCLOSPORINE (View Cyclosporine Review and Cyclosporine Label ), PREDNISONE (View Prednisone Review and Prednisone Label ), PHENYTOIN (View Phenytoin Review and Phenytoin Label ).

6909309-0 | Convulsion, Haemolytic Anaemia, Herpes Zoster, Ovarian Failure
Adverse event was reported on Jul 20, 2010 by a Female patient taking Busulfex (View Usage) (Dosage: 0.8 Mg/kg Q6hr Intravenous) was diagnosed with stem cell transplant and. Location: UNITED STATES , child 10 years of age, After Busulfex was administered, patient had the following side effects: convulsion, haemolytic anaemia, herpes zoster, ovarian failure. During the same period patient was treated with ANTITHYMOCYTE IMMUNOGLOBULIN (ANTITHYMOCYTE IMMUOGLOBULIN) (View Antithymocyte Immunoglobulin (antithymocyte Immuoglobulin) Review and Antithymocyte Immunoglobulin (antithymocyte Immuoglobulin) Label ), CYCLOPHOSPHAMIDE (View Cyclophosphamide Review and Cyclophosphamide Label ), CYCLOSPORINE (View Cyclosporine Review and Cyclosporine Label ), MYCOPHENOLATE MOFETIL (View Mycophenolate Mofetil Review and Mycophenolate Mofetil Label ), PHENYTOIN (View Phenytoin Review and Phenytoin Label ).

6909283-7 | Acute Graft Versus Host Disease In Intestine, Acute Graft Versus Host Disease In Liver, Chronic Graft Versus Host Disease, Haemolytic Anaemia, Herpes Zoster
on Jul 20, 2010 Male patient from UNITED STATES , child 10 years of age, was diagnosed with stem cell transplant and was treated with Busulfex (View Usage). Patient experienced the following unwanted or unexpected effects: acute graft versus host disease in intestine, acute graft versus host disease in liver, chronic graft versus host disease, haemolytic anaemia, herpes zoster. Busulfex dosage: 0.8 Mg/kg Q6hr Intravenous. During the same period patient was treated with ANTI THYMOCYTE GLOBULIN NOS (View Anti-thymocyte Globulin Nos Review and Anti-thymocyte Globulin Nos Label ), CYCLOPHOSPHAMIDE (View Cyclophosphamide Review and Cyclophosphamide Label ), CYCLOSPORINE (View Cyclosporine Review and Cyclosporine Label ), PREDNISONE (View Prednisone Review and Prednisone Label ), PHENYTOIN (View Phenytoin Review and Phenytoin Label ).

6909282-5 | Ataxia, Pneumonia, Restrictive Pulmonary Disease, Stem Cell Transplant
on Jul 20, 2010 Male patient from UNITED STATES , child 4 years of age, was diagnosed with stem cell transplant and was treated with Busulfex (View Usage). Patient had the following side effects: ataxia (What is ataxia?), pneumonia (What is pneumonia?), restrictive pulmonary disease, stem cell transplant. Busulfex dosage: 0.8 Mg/kg Q6hr Intravenous. During the same period patient was treated with ANTI THYMOCYTE GLOBULIN NOS (View Anti-thymocyte Globulin Nos Review and Anti-thymocyte Globulin Nos Label ), CYCLOPHOSPHAMIDE (View Cyclophosphamide Review and Cyclophosphamide Label ), PREDNISONE (View Prednisone Review and Prednisone Label ), CYCLOSPORINE (View Cyclosporine Review and Cyclosporine Label ), PHENYTOIN (View Phenytoin Review and Phenytoin Label ).

6909047-4 | Chronic Graft Versus Host Disease, Convulsion, Encephalitis, Reversible Posterior Leukoencephalopathy Syndrome
Patient was taking Busulfex (View Usage). After Busulfex was administered, patient had the following side effects: chronic graft versus host disease, convulsion, encephalitis (What is encephalitis?), reversible posterior leukoencephalopathy syndrome on Jul 20, 2010 from UNITED STATES Additional patient health information: Male patient , child 7 years of age, was diagnosed with stem cell transplant and. Busulfex dosage: 0.8 Mg/kg, Q6hr, Intravenous. During the same period patient was treated with ANTI THYMOCYTE GLOBULIN NOS (View Anti-thymocyte Globulin Nos Review and Anti-thymocyte Globulin Nos Label ), CYCLOPHOSPHAMIDE (View Cyclophosphamide Review and Cyclophosphamide Label ), CYCLOSPORINE (View Cyclosporine Review and Cyclosporine Label ), MYCOPHENOLATE MOFETIL (View Mycophenolate Mofetil Review and Mycophenolate Mofetil Label ), PHENYTOIN (View Phenytoin Review and Phenytoin Label ), FILGRASTIM (FILGRASTIM) (View Filgrastim (filgrastim) Review and Filgrastim (filgrastim) Label ), PREDNISONE (View Prednisone Review and Prednisone Label ).

6909043-7 | Restrictive Pulmonary Disease
Adverse event was reported on Jul 20, 2010 by a Male patient taking Busulfex (View Usage) (Dosage: 0.8 Mg/kg Unk Intravenous) was diagnosed with stem cell transplant and. Location: UNITED STATES , child 11 years of age, Patient experienced the following unwanted or unexpected effects: restrictive pulmonary disease. During the same period patient was treated with ANTI THYMOCYTE GLOBULIN NOS (View Anti-thymocyte Globulin Nos Review and Anti-thymocyte Globulin Nos Label ), CYCLOPHOSPHAMIDE (View Cyclophosphamide Review and Cyclophosphamide Label ), CYCLOSPORINE (View Cyclosporine Review and Cyclosporine Label ), PHENYTOIN (View Phenytoin Review and Phenytoin Label ), FILGRASTIM (FILGRASTIM) (View Filgrastim (filgrastim) Review and Filgrastim (filgrastim) Label ), PREDNISONE (View Prednisone Review and Prednisone Label ).

6909031-0 | Acute Graft Versus Host Disease In Intestine, Restrictive Pulmonary Disease
on Jul 20, 2010 Male patient from UNITED STATES , child 9 years of age, was diagnosed with stem cell transplant and was treated with Busulfex (View Usage). Patient had the following side effects: acute graft versus host disease in intestine, restrictive pulmonary disease. Busulfex dosage: 0.8 Mg/kg, Q8hr, Intravenous. During the same period patient was treated with ANTITHYMOCYTE IMUNOGLOBULIN (ANTITHYMOCYTE IMMUNOGLOBULIN) (View Antithymocyte Imunoglobulin (antithymocyte Immunoglobulin) Review and Antithymocyte Imunoglobulin (antithymocyte Immunoglobulin) Label ), CYCLOPHOSPHAMIDE (View Cyclophosphamide Review and Cyclophosphamide Label ), CYCLOSPORINE (View Cyclosporine Review and Cyclosporine Label ), PREDNISONE (View Prednisone Review and Prednisone Label ), PHENYTOIN (View Phenytoin Review and Phenytoin Label ), FILGRASTIM (FILGRASTIM) (View Filgrastim (filgrastim) Review and Filgrastim (filgrastim) Label ).

6846852-7 | Diarrhoea, Febrile Neutropenia, Infection, Mucosal Inflammation, Renal Failure
on Jun 29, 2010 Male patient from AUSTRALIA , 49 years of age, was treated with Busulfex (View Usage). After Busulfex was administered, patient had the following side effects: diarrhoea, febrile neutropenia, infection (What is infection?), mucosal inflammation, renal failure. Busulfex dosage: 2.67 Mg/kg, Daily Dose, Intravenous. During the same period patient was treated with THIOTEPA (View Thiotepa Review and Thiotepa Label ), CYCLOPHTOSPHAMIDE (CYCLOPHOSPHAMIDE) (View Cyclophtosphamide (cyclophosphamide) Review and Cyclophtosphamide (cyclophosphamide) Label ).

6831890-0 | Blood Potassium Increased, Diarrhoea, Febrile Neutropenia, Hepatic Function Abnormal, Leukaemia Recurrent, Malaise, Nausea, Renal Impairment, Staphylococcal Sepsis
Patient was taking Busulfex (View Usage). Patient experienced the following unwanted or unexpected effects: blood potassium increased, diarrhoea, febrile neutropenia, hepatic function abnormal, leukaemia recurrent, malaise, nausea (What is nausea?), renal impairment, staphylococcal sepsis on Jun 22, 2010 from JAPAN Additional patient health information: Female patient , 63 years of age, was diagnosed with stem cell transplant and. Busulfex dosage: 6 Ml, Daily Dose, Intravenous. During the same period patient was treated with FLUDARABINE PHOSPHATE (View Fludarabine Phosphate Review and Fludarabine Phosphate Label ), PHENYTOIN (View Phenytoin Review and Phenytoin Label ), FILGRASTIM (FILGRASTIM) (View Filgrastim (filgrastim) Review and Filgrastim (filgrastim) Label ), TACROLIMUS (View Tacrolimus Review and Tacrolimus Label ).

6829082-4 | Leukaemia Recurrent
Adverse event was reported on Jun 20, 2010 by a Male patient taking Busulfex (View Usage) (Dosage: Intravenous) was diagnosed with stem cell transplant and. Location: JAPAN , 52 years of age, Patient had the following side effects: leukaemia recurrent. During the same period patient was treated with FLUADARABINE (View Fluadarabine Review and Fluadarabine Label ).

6828909-X | Acute Graft Versus Host Disease, Chronic Graft Versus Host Disease, Leukaemia Recurrent
on Jun 20, 2010 Male patient from JAPAN , 64 years of age, was diagnosed with stem cell transplant and was treated with Busulfex (View Usage). After Busulfex was administered, patient had the following side effects: acute graft versus host disease, chronic graft versus host disease, leukaemia recurrent. Busulfex dosage: Oral. During the same period patient was treated with FLUDARADINE (FLUDARABINE) (View Fludaradine (fludarabine) Review and Fludaradine (fludarabine) Label ).

6828908-8 | Leukaemia Recurrent
on Jun 20, 2010 Female patient from JAPAN , 63 years of age, was diagnosed with stem cell transplant and was treated with Busulfex (View Usage). Patient experienced the following unwanted or unexpected effects: leukaemia recurrent. Busulfex dosage: Intravenous. During the same period patient was treated with FLUDARABINE PHOSPHATE (View Fludarabine Phosphate Review and Fludarabine Phosphate Label ).

6828907-6 | Acute Graft Versus Host Disease, Engraft Failure
Patient was taking Busulfex (View Usage). Patient had the following side effects: acute graft versus host disease, engraft failure on Jun 30, 2010 from JAPAN Additional patient health information: Female patient , 28 years of age, was diagnosed with stem cell transplant and. Busulfex dosage: Oral.

6822123-X | Acute Graft Versus Host Disease In Skin, Acute Lymphocytic Leukaemia Recurrent, Alanine Aminotransferase Increased, Aspartate Aminotransferase Increased, Cachexia, Chronic Graft Versus Host Disease, Encephalitis, Gamma-glutamyltransferase Increased, Glomerulonephritis Membranous
Adverse event was reported on Jun 21, 2010 by a Male patient taking Busulfex (View Usage) (Dosage: 16mg/kg) was diagnosed with stem cell transplant and. Location: FRANCE , 30 years of age, After Busulfex was administered, patient had the following side effects: acute graft versus host disease in skin, acute lymphocytic leukaemia recurrent, alanine aminotransferase increased, aspartate aminotransferase increased, cachexia, chronic graft versus host disease, encephalitis (What is encephalitis?), gamma-glutamyltransferase increased, glomerulonephritis membranous. During the same period patient was treated with CYCLOPHOSPHAMIDE (View Cyclophosphamide Review and Cyclophosphamide Label ). Patient was hospitalized.

6809833-5 | Acute Graft Versus Host Disease In Skin, Aspartate Aminotransferase Increased, Bronchiolitis, Chronic Graft Versus Host Disease, Cystitis Haemorrhagic, Cytomegalovirus Infection, Diarrhoea, Gamma-glutamyltransferase Increased
on Jun 14, 2010 Male patient from POLAND , 30 years of age, was diagnosed with stem cell transplant and was treated with Busulfex (View Usage). Patient experienced the following unwanted or unexpected effects: acute graft versus host disease in skin, aspartate aminotransferase increased, bronchiolitis, chronic graft versus host disease, cystitis haemorrhagic, cytomegalovirus infection (What is cytomegalovirus infection?), diarrhoea, gamma-glutamyltransferase increased. Busulfex dosage: 16 Mg/kg,. During the same period patient was treated with CYCLOPHOSPHAMIDE (View Cyclophosphamide Review and Cyclophosphamide Label ), ATG (ANTILYMPHOCYTE IMMUNOGLOBULIN (HORSE)) (View Atg (antilymphocyte Immunoglobulin (horse)) Review and Atg (antilymphocyte Immunoglobulin (horse)) Label ), CYCLOSPORINE (View Cyclosporine Review and Cyclosporine Label ). Patient was hospitalized.

6809829-3 | Acute Graft Versus Host Disease In Intestine, Acute Graft Versus Host Disease In Skin, Chronic Graft Versus Host Disease, Pancreatic Atrophy, Sicca Syndrome, Steatorrhoea
on Jun 10, 2010 Female patient from JAPAN , 41 years of age, was diagnosed with stem cell transplant and was treated with Busulfex (View Usage). Patient had the following side effects: acute graft versus host disease in intestine, acute graft versus host disease in skin, chronic graft versus host disease, pancreatic atrophy, sicca syndrome, steatorrhoea. Busulfex dosage: Intravenous. During the same period patient was treated with CYCLOPHOSPHAMIDE (View Cyclophosphamide Review and Cyclophosphamide Label ).

6783252-2 | Acute Graft Versus Host Disease, Transplant Failure
Patient was taking Busulfex (View Usage). After Busulfex was administered, patient had the following side effects: acute graft versus host disease, transplant failure on Jun 03, 2010 from JAPAN Additional patient health information: Female patient , 28 years of age, was diagnosed with stem cell transplant and. Busulfex dosage: . During the same period patient was treated with FLUDARABINE PHOSPHATE (View Fludarabine Phosphate Review and Fludarabine Phosphate Label ).

6782520-8 | Acute Respiratory Failure, Confusional State, Cytomegalovirus Infection, Hepatotoxicity, Interstitial Lung Disease, Toxoplasmosis
Adverse event was reported on Jun 07, 2010 by a Female patient taking Busulfex (View Usage) (Dosage: Oral) was diagnosed with stem cell transplant and. Location: FRANCE , 15 years of age, Patient experienced the following unwanted or unexpected effects: acute respiratory failure, confusional state, cytomegalovirus infection (What is cytomegalovirus infection?), hepatotoxicity, interstitial lung disease, toxoplasmosis. During the same period patient was treated with CYCLOPHOSPHAMIDE (View Cyclophosphamide Review and Cyclophosphamide Label ), ATG (ANTILYMPHOCYTE IMMUNOGLOBULIN (HORSE) (View Atg (antilymphocyte Immunoglobulin (horse) Review and Atg (antilymphocyte Immunoglobulin (horse) Label ), CYCLOSPORINE (View Cyclosporine Review and Cyclosporine Label ), CORTICOSTEROIDS FOR SYSTEMIC USE (View Corticosteroids For Systemic Use Review and Corticosteroids For Systemic Use Label ), CEFTAZIDIME (View Ceftazidime Review and Ceftazidime Label ), VANCOMYCIN (View Vancomycin Review and Vancomycin Label ), METRONIDAZOLE (View Metronidazole Review and Metronidazole Label ).

6782519-1 | Leukaemia Recurrent
on Jun 03, 2010 Male patient from JAPAN , 52 years of age, was diagnosed with stem cell transplant and was treated with Busulfex (View Usage). Patient had the following side effects: leukaemia recurrent. Busulfex dosage: . During the same period patient was treated with FLUDARABINE (View Fludarabine Review and Fludarabine Label ).

6782518-X | Leukaemia Recurrent
on Jun 03, 2010 Female patient from JAPAN , 63 years of age, was diagnosed with stem cell transplant and was treated with Busulfex (View Usage). After Busulfex was administered, patient had the following side effects: leukaemia recurrent. Busulfex dosage: . During the same period patient was treated with FLUDARABINE (View Fludarabine Review and Fludarabine Label ).

6782517-8 | Acute Graft Versus Host Disease, Chronic Graft Versus Host Disease, Leukaemia Recurrent
Patient was taking Busulfex (View Usage). Patient experienced the following unwanted or unexpected effects: acute graft versus host disease, chronic graft versus host disease, leukaemia recurrent on Jun 03, 2010 from JAPAN Additional patient health information: Male patient , 64 years of age, was diagnosed with stem cell transplant and. Busulfex dosage: . During the same period patient was treated with FLUDARABINE PHOSPHATE (View Fludarabine Phosphate Review and Fludarabine Phosphate Label ).

6744234-X | Aspergillus Test, Bone Marrow Failure, Brain Stem Infarction, Cerebral Infarction, Cytomegalovirus Test Positive, Lobar Pneumonia, Myocardial Infarction, Pseudomonas Infection, Sputum Culture Positive
Adverse event was reported on May 11, 2010 by a Male patient taking Busulfex (View Usage) (Dosage: 42 Mg, Daily Dose, Intravenous) was diagnosed with stem cell transplant, prophylaxis and. Location: JAPAN , 56 years of age, Patient had the following side effects: aspergillus test, bone marrow failure, brain stem infarction, cerebral infarction, cytomegalovirus test positive, lobar pneumonia, myocardial infarction, pseudomonas infection, sputum culture positive. During the same period patient was treated with FLUDARABINE PHOSPHATE (45 Mg, Daily Dose, Intravenous) (View Fludarabine Phosphate Review and Fludarabine Phosphate Label ), TACROLIMUS (1.6 Mg, Daily Dose, Intravenous) (View Tacrolimus Review and Tacrolimus Label ), METHOTREXATE (1.5 Mg, Daily Dose, Intravenous; 10 Mg, Daily Dose, Intravenous) (View Methotrexate Review and Methotrexate Label ), DEPAKENE (View Depakene Review and Depakene Label ).

6743679-1 | Depressed Level Of Consciousness, Diarrhoea, Hypoxia, Ileus Paralytic, Intestinal Obstruction, Multi-organ Failure, Pneumonia Bacterial, Pyrexia, Sepsis
on May 11, 2010 Male patient from JAPAN , 59 years of age, was diagnosed with stem cell transplant, prophylaxis and was treated with Busulfex (View Usage). After Busulfex was administered, patient had the following side effects: depressed level of consciousness, diarrhoea, hypoxia, ileus paralytic, intestinal obstruction, multi-organ failure, pneumonia bacterial, pyrexia, sepsis (What is sepsis?). Busulfex dosage: 45 Mg, Qid, Intravenous. During the same period patient was treated with FLUDARABINE PHOSPHATE (30 Mg/m2) (View Fludarabine Phosphate Review and Fludarabine Phosphate Label ), METHOTREXATE (15 Mg, Daily Dose: Intravenous; 10 Mg, Daily Dose: Intravenous, 10 Mg, Daily Dose; Intravenous) (View Methotrexate Review and Methotrexate Label ), TACROLIMUS (1.6 Mg, Daily Dose; Intravenous) (View Tacrolimus Review and Tacrolimus Label ), ETOPOSIDE (View Etoposide Review and Etoposide Label ), DEPAKENE (View Depakene Review and Depakene Label ).

6740651-2 | Ewing's Sarcoma, Paraparesis
on May 12, 2010 Male patient from CROATIA (local name: Hrvatska) , 17 years of age, was diagnosed with stem cell transplant and was treated with Busulfex (View Usage). Patient experienced the following unwanted or unexpected effects: ewing's sarcoma, paraparesis. Busulfex dosage: Intravenous. During the same period patient was treated with CYCLOPHOSPHAMIDE (View Cyclophosphamide Review and Cyclophosphamide Label ).

6740647-0 | Acute Graft Versus Host Disease In Intestine, Acute Graft Versus Host Disease In Skin, Acute Respiratory Distress Syndrome, Cytomegalovirus Infection, Epstein-barr Virus Infection, Febrile Neutropenia, Graft Versus Host Disease In Lung, Pneumocystis Jiroveci Infection, Renal Failure
Patient was taking Busulfex (View Usage). Patient had the following side effects: acute graft versus host disease in intestine, acute graft versus host disease in skin, acute respiratory distress syndrome, cytomegalovirus infection (What is cytomegalovirus infection?), epstein-barr virus infection, febrile neutropenia, graft versus host disease in lung, pneumocystis jiroveci infection, renal failure on May 12, 2010 from SWITZERLAND Additional patient health information: Female patient , child 10 years of age, was diagnosed with stem cell transplant and. Busulfex dosage: . During the same period patient was treated with CYCLOPHOSPHAMIDE (View Cyclophosphamide Review and Cyclophosphamide Label ).